DK1091930T3 - C-terminalt modificerede oxamyldipeptider som inhibitorer af ICE/ced-3-familien af cysteinproteaser - Google Patents

C-terminalt modificerede oxamyldipeptider som inhibitorer af ICE/ced-3-familien af cysteinproteaser

Info

Publication number
DK1091930T3
DK1091930T3 DK99932211T DK99932211T DK1091930T3 DK 1091930 T3 DK1091930 T3 DK 1091930T3 DK 99932211 T DK99932211 T DK 99932211T DK 99932211 T DK99932211 T DK 99932211T DK 1091930 T3 DK1091930 T3 DK 1091930T3
Authority
DK
Denmark
Prior art keywords
ced
inhibitors
ice
family
cysteine proteases
Prior art date
Application number
DK99932211T
Other languages
Danish (da)
English (en)
Inventor
Donald S Karanewsky
Robert J Ternansky
Original Assignee
Idun Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26784233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1091930(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1091930T3 publication Critical patent/DK1091930T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3264—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99932211T 1998-07-02 1999-07-01 C-terminalt modificerede oxamyldipeptider som inhibitorer af ICE/ced-3-familien af cysteinproteaser DK1091930T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9168998P 1998-07-02 1998-07-02
US09/177,549 US6197750B1 (en) 1998-07-02 1998-10-22 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
PCT/US1999/015074 WO2000001666A1 (fr) 1998-07-02 1999-07-01 OXAMYL DIPEPTIDES A TERMINAL C MODIFIE EN TANT QU'INHIBITEURS DE LA FAMILLE ICE/ced-3 DES PROTEASES DE CYSTEINE

Publications (1)

Publication Number Publication Date
DK1091930T3 true DK1091930T3 (da) 2007-04-02

Family

ID=26784233

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99932211T DK1091930T3 (da) 1998-07-02 1999-07-01 C-terminalt modificerede oxamyldipeptider som inhibitorer af ICE/ced-3-familien af cysteinproteaser
DK06125650T DK1754475T3 (da) 1998-07-02 1999-07-01 Anvendelse af C-terminal modificerede oxamyl dipeptider som inhibitorer af ice/ced-3 familien af cysteinproteaser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06125650T DK1754475T3 (da) 1998-07-02 1999-07-01 Anvendelse af C-terminal modificerede oxamyl dipeptider som inhibitorer af ice/ced-3 familien af cysteinproteaser

Country Status (22)

Country Link
US (1) US6197750B1 (fr)
EP (2) EP1754475B1 (fr)
JP (1) JP3815968B2 (fr)
KR (1) KR100804432B1 (fr)
CN (1) CN1159289C (fr)
AT (2) ATE442843T1 (fr)
AU (1) AU752339B2 (fr)
BR (1) BR9911675A (fr)
CA (1) CA2336474C (fr)
CY (1) CY1108088T1 (fr)
DE (2) DE69934405T2 (fr)
DK (2) DK1091930T3 (fr)
ES (2) ES2330663T3 (fr)
HU (1) HUP0102898A3 (fr)
ID (1) ID28263A (fr)
IL (1) IL140554A0 (fr)
MX (1) MXPA00013014A (fr)
NO (1) NO20006544L (fr)
NZ (1) NZ509025A (fr)
PL (1) PL207578B1 (fr)
PT (1) PT1091930E (fr)
WO (1) WO2000001666A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1647279A3 (fr) * 1996-09-12 2006-04-26 Idun Pharmaceuticals, Inc. Inhibition de l'apoptose au moyen d'inhibiteurs de la famille CED-3/ICE (enzyme de conversion de l'interleukine-1 bêta
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
DK1064298T3 (da) * 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
CN1176941C (zh) 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
WO2001044214A1 (fr) * 1999-12-03 2001-06-21 Ono Pharmaceutical Co., Ltd. Derives d'oxadiazole et medicaments contenant ces derives utiles comme ingredients actifs
US6790989B2 (en) * 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6515173B1 (en) * 2000-01-13 2003-02-04 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
AU2001253633A1 (en) * 2000-04-17 2001-10-30 Idun Pharmaceuticals, Inc. Inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002245649A1 (en) * 2001-03-02 2002-09-19 Idun Pharmaceuticals, Inc. Methods, compositions and kits for preserving antigenicity
WO2003062192A1 (fr) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US7960398B2 (en) * 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
US7923433B2 (en) 2002-10-09 2011-04-12 Activx Biosciences, Inc. Activity-based probes and methods of their preparation and use
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
US7749999B2 (en) * 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CA2545733A1 (fr) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
SG150547A1 (en) * 2004-03-12 2009-03-30 Vertex Pharma Processes and intermediates
CA2567080A1 (fr) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Traitement de maladies a l'aide d'inhibiteurs de l'ice
ATE543803T1 (de) 2004-11-24 2012-02-15 Vertex Pharma 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
CA2614622A1 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Nouvelle combinaison d'un anticorps anti-madcam et d'un inhibiteur de caspase anti-fibrotique pour le traitement de la fibrose du foie
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
KR101125932B1 (ko) * 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US10100037B2 (en) * 2013-03-15 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
ES2751652T3 (es) 2014-05-12 2020-04-01 Conatus Pharmaceuticals Inc Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
EP3265440A1 (fr) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Emricasan deutéré
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
TW201739734A (zh) * 2016-05-11 2017-11-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Caspase抑制劑及其藥物組合物、用途和治療方法
RU2019113150A (ru) 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
ES2964985T3 (es) 2016-12-23 2024-04-10 Univ Leland Stanford Junior Compuestos sonda basados en actividad, composiciones y métodos de uso
WO2018133870A1 (fr) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 Composé cyclique lié en tant qu'inhibiteur de caspase
AU2019233195A1 (en) * 2018-03-13 2020-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. A crystal of a caspase inhibitor
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
WO2022123062A1 (fr) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocage de la caspase et/ou de la fasl pour prévenir une issue fatale chez des patients atteints de la covid-19
WO2023161940A1 (fr) * 2022-02-25 2023-08-31 Carmel-Haifa University Economic Corporation Ltd. Protéine associée à l'apoptose dans les composés mimétiques de la voie de signalisation tgf-beta (arts), compositions, procédés et utilisations associés dans l'induction de l'apoptose
CN119529128B (zh) * 2024-11-21 2026-04-17 中国科学院昆明植物研究所 具有抗白血病活性的当归多糖aps-1 ii 13糖和子结构9糖的制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0618223A3 (fr) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires.
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Also Published As

Publication number Publication date
CA2336474C (fr) 2008-04-29
ES2276520T3 (es) 2007-06-16
HUP0102898A2 (hu) 2002-01-28
KR20010083079A (ko) 2001-08-31
US6197750B1 (en) 2001-03-06
WO2000001666A1 (fr) 2000-01-13
JP2002519406A (ja) 2002-07-02
DK1754475T3 (da) 2009-11-09
NO20006544L (no) 2001-02-28
ATE348096T1 (de) 2007-01-15
NZ509025A (en) 2003-05-30
CN1159289C (zh) 2004-07-28
EP1091930B1 (fr) 2006-12-13
DE69934405T2 (de) 2007-10-31
DE69941440D1 (de) 2009-10-29
MXPA00013014A (es) 2004-04-02
NO20006544D0 (no) 2000-12-21
IL140554A0 (en) 2002-02-10
KR100804432B1 (ko) 2008-02-20
EP1754475A1 (fr) 2007-02-21
PT1091930E (pt) 2007-02-28
CA2336474A1 (fr) 2000-01-13
JP3815968B2 (ja) 2006-08-30
ATE442843T1 (de) 2009-10-15
AU752339B2 (en) 2002-09-19
CY1108088T1 (el) 2014-02-12
EP1091930A1 (fr) 2001-04-18
ID28263A (id) 2001-05-10
CN1313846A (zh) 2001-09-19
EP1754475B1 (fr) 2009-09-16
DE69934405D1 (de) 2007-01-25
PL345350A1 (en) 2001-12-17
AU4856999A (en) 2000-01-24
HUP0102898A3 (en) 2002-09-30
HK1036616A1 (en) 2002-01-11
PL207578B1 (pl) 2011-01-31
ES2330663T3 (es) 2009-12-14
BR9911675A (pt) 2002-02-05

Similar Documents

Publication Publication Date Title
DK1091930T3 (da) C-terminalt modificerede oxamyldipeptider som inhibitorer af ICE/ced-3-familien af cysteinproteaser
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
MXPA02011466A (es) Derivados de fenilglicina..
DE602004029866D1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
SE0201976D0 (sv) Novel compounds
EA200300050A1 (ru) Гликопептидфосфонатные производные
ES2169880T3 (es) Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
CR20110172A (es) Composiciones antimicrobianas
TR200003004T2 (tr) Kalpain önleyicileri olarak heterosiklik ikame edilmiş amidler
NO990667D0 (no) Depeptid-benzamidin som kinogenase-inhibitor
AR024040A1 (es) Derivados de furanona como inhibidores de la catepsina s
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
MXPA03010179A (es) Eteres de arilsulfonamida y metodos de uso de los mismos.
AR021241A1 (es) Inhibidores de proteasas
WO2002057246A3 (fr) Inhibiteurs de la cruzipaine et d'autres cysteines proteases
ATE340569T1 (de) Verwendung eines neuen mittels zur verhütung von infektionen
DE60134814D1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
ATE214692T1 (de) Metalloproteinase-inhibitoren
WO2002057248A3 (fr) Inhibiteurs de la cruzipain et autres cysteine proteases
WO2001079162A3 (fr) Inhibiteurs de la famille ice/ced-3 de cysteines proteases
DE60203726D1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DK1119351T3 (da) Anvendelse af katecholderivater som proteinaseinhibitorer
NO20040378L (no) Osteogeniske vekstoligopeptider som stimulanter av hematopoese